Published in Indian J Nucl Med on April 01, 2011
Radiation safety audit of a high volume Nuclear Medicine Department. Indian J Nucl Med (2014) 0.75
Ga-68 DOTANOC PET/CT imaging in detection of primary site in patients with metastatic neuroendocrine tumours of unknown origin and its impact on clinical decision making: experience from a tertiary care centre in India. J Gastrointest Oncol (2016) 0.75
Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev (2003) 2.92
Processing of generator-produced 68Ga for medical application. J Nucl Med (2007) 2.75
Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med (1996) 2.51
Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med (2001) 1.71
The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J Nucl Med (2010) 1.48
(68)Ga-labeled peptides in tumor imaging. J Nucl Med (2005) 1.45
Radiation dose to technicians per nuclear medicine procedure: comparison between technetium-99m, gallium-67, and iodine-131 radiotracers and fluorine-18 fluorodeoxyglucose. Eur J Nucl Med (1997) 1.42
SPECT/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours. Clin Endocrinol (Oxf) (2003) 1.22
68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med (2010) 1.19
68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging (2007) 1.15
Radiation dose rates from patients undergoing PET: implications for technologists and waiting areas. Eur J Nucl Med (2000) 1.07
Finger doses for staff handling radiopharmaceuticals in nuclear medicine. J Nucl Med Technol (2006) 1.04
[Radiation exposure of patients during 68Ga-DOTATOC PET/CT examinations]. Nuklearmedizin (2009) 1.02
Optimal buffer choice of the radiosynthesis of (68)Ga-Dotatoc for clinical application. Nucl Med Commun (2010) 0.85
Radiation dose to the hands in nuclear medicine. Nucl Med Commun (1991) 0.85
The use of extremity dosemeters in a hospital environment. Radiat Prot Dosimetry (2006) 0.81
Somatostatin receptors and breast cancer. Q J Nucl Med (1998) 0.79
An assessment of finger doses received by staff while preparing and injecting radiopharmaceuticals. Nucl Med Commun (1997) 0.79
Investigation using an advanced extremity gamma instrumentation system of options for shielding the hand during the preparation and injection of radiopharmaceuticals. J Radiol Prot (2003) 0.78
Reduction of extremity dose in the radiopharmacy. Nucl Med Commun (1997) 0.78
Somatostatin receptor scintigraphy: a first-line imaging modality for gastroenteropancreatic neuroendocrine tumors. Gastroenterology (1998) 0.78
Paediatric personnel extremity dose study. Br J Radiol (2002) 0.78
Monitoring radiation dose to the hands in nuclear medicine: location of dosemeters. Nucl Med Commun (1987) 0.78
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res (2006) 4.20
Maintenance and polarization of human TH2 central memory T cells by thymic stromal lymphopoietin-activated dendritic cells. Immunity (2006) 2.95
Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell (2004) 2.71
Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. J Natl Cancer Inst (2006) 2.71
Filamin is essential in actin cytoskeletal assembly mediated by p21-activated kinase 1. Nat Cell Biol (2002) 2.45
Pak protein kinases and their role in cancer. Cancer Metastasis Rev (2009) 2.44
MicroRNA-7, a homeobox D10 target, inhibits p21-activated kinase 1 and regulates its functions. Cancer Res (2008) 2.32
Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair. Cell Cycle (2009) 2.31
Synergistic inhibition of hepatocellular carcinoma growth by cotargeting chromatin modifying enzymes and poly (ADP-ribose) polymerases. Hepatology (2012) 2.23
Modified Trachlight for management of difficult pediatric airway. Paediatr Anaesth (2008) 2.19
SRC-3Delta4 mediates the interaction of EGFR with FAK to promote cell migration. Mol Cell (2010) 2.18
Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation. Mol Endocrinol (2002) 2.18
Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res (2008) 2.15
Pak1 phosphorylation of snail, a master regulator of epithelial-to-mesenchyme transition, modulates snail's subcellular localization and functions. Cancer Res (2005) 2.09
Tc-99m ethylcysteinate dimer SPECT in the differential diagnosis of dementias. Neurol India (2010) 2.04
MOF and histone H4 acetylation at lysine 16 are critical for DNA damage response and double-strand break repair. Mol Cell Biol (2010) 2.03
The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol (2002) 2.03
Suicide an emerging public health problem: evidence from rural Haryana, India. Indian J Public Health (2013) 2.03
Cystatin C-based glomerular filtration rate estimating equations in early chronic kidney disease. Indian Pediatr (2014) 2.02
Characterization of RNase R-digested cellular RNA source that consists of lariat and circular RNAs from pre-mRNA splicing. Nucleic Acids Res (2006) 2.00
Metastasis tumor antigens, an emerging family of multifaceted master coregulators. J Biol Chem (2006) 2.00
Dynein light chain 1, a p21-activated kinase 1-interacting substrate, promotes cancerous phenotypes. Cancer Cell (2004) 1.93
Taxonomic studies on genus Tetramorium Mayr (Hymenoptera, Formicidae) with report of two new species and three new records including a tramp species from India with a revised key. Zookeys (2012) 1.92
The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane. Proc Natl Acad Sci U S A (2004) 1.89
Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway. Cancer Res (2006) 1.82
P21-activated kinase-1 phosphorylates and transactivates estrogen receptor-alpha and promotes hyperplasia in mammary epithelium. EMBO J (2002) 1.75
Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis. Cancer Res (2006) 1.72
Retracted Regulation of NF-kappaB circuitry by a component of the nucleosome remodeling and deacetylase complex controls inflammatory response homeostasis. J Biol Chem (2010) 1.71
p21-activated kinase-1 signaling mediates cyclin D1 expression in mammary epithelial and cancer cells. J Biol Chem (2003) 1.70
Retracted Metastasis-associated protein 1 deregulation causes inappropriate mammary gland development and tumorigenesis. Development (2004) 1.67
Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem (2008) 1.66
Phosphorylation of Exo1 modulates homologous recombination repair of DNA double-strand breaks. Nucleic Acids Res (2009) 1.66
MTA1, a transcriptional activator of breast cancer amplified sequence 3. Proc Natl Acad Sci U S A (2006) 1.66
Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem (2005) 1.65
Characterization of a novel PERK kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res (2013) 1.63
Role of 68Ga-DOTATOC PET/CT in initial evaluation of patients with suspected bronchopulmonary carcinoid. Eur J Nucl Med Mol Imaging (2014) 1.63
Critical evaluation of the claims made by pharmaceutical companies in drug promotional material in Pakistan. J Pharm Pharm Sci (2006) 1.63
Disseminated tuberculosis masquerading as metastatic breast carcinoma on PET-CT. Clin Nucl Med (2008) 1.61
The vascular endothelial growth factor (VEGF) receptor Flt-1 (VEGFR-1) modulates Flk-1 (VEGFR-2) signaling during blood vessel formation. Am J Pathol (2004) 1.61
Arpc1b, a centrosomal protein, is both an activator and substrate of Aurora A. J Cell Biol (2010) 1.60
Potential role of a novel transcriptional coactivator PELP1 in histone H1 displacement in cancer cells. Cancer Res (2004) 1.59
Biliary microlithiasis in patients with idiopathic acute pancreatitis and unexplained biliary pain: response to therapy. J Gastroenterol Hepatol (2004) 1.59
P21-activated kinase 1 regulation of estrogen receptor-alpha activation involves serine 305 activation linked with serine 118 phosphorylation. Cancer Res (2006) 1.58
RNA sequencing of cancer reveals novel splicing alterations. Sci Rep (2013) 1.57
Retracted Stimulation of inducible nitric oxide by hepatitis B virus transactivator protein HBx requires MTA1 coregulator. J Biol Chem (2009) 1.56
Thyroid scintigraphy in detecting dual ectopic thyroid: a review. Eur J Nucl Med Mol Imaging (2008) 1.54
Noninvasive imaging surrogate of angiogenesis in osteosarcoma. Pediatr Blood Cancer (2010) 1.54
Mechanism and management of AKT inhibitor-induced hyperglycemia. Clin Cancer Res (2009) 1.53
HSSB1 and hSSB2 form similar multiprotein complexes that participate in DNA damage response. J Biol Chem (2009) 1.52
Community Perception and Client Satisfaction about the Primary Health Care Services in an Urban Resettlement Colony of New Delhi. Indian J Community Med (2008) 1.52
AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines. Blood (2008) 1.52
N-(4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists. J Med Chem (2009) 1.52
Dyke-Davidoff-Masson syndrome. Indian Pediatr (2008) 1.51
Nuclear receptor coregulators in cancer biology. Cancer Res (2009) 1.51
Hallmarks of mechanochemistry: from nanoparticles to technology. Chem Soc Rev (2013) 1.51
UnPAKing the class differences among p21-activated kinases. Trends Biochem Sci (2008) 1.51
Functional inactivation of a transcriptional corepressor by a signaling kinase. Nat Struct Biol (2003) 1.50
Functional and biological properties of the nuclear receptor coregulator PELP1/MNAR. Nucl Recept Signal (2007) 1.48
Age-related changes in the metabolic activity and distribution of the red marrow as demonstrated by 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography. Mol Imaging Biol (2007) 1.48
Evaluation of mediastinal lymph nodes using F-FDG PET-CT scan and its histopathologic correlation. Ann Thorac Med (2011) 1.47
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci U S A (2006) 1.46
Structural basis for processivity and single-strand specificity of RNase II. Mol Cell (2006) 1.44
Signaling regulation of genomic and nongenomic functions of estrogen receptors. Cancer Lett (2005) 1.44
Dual ectopic thyroid: case series and review of the literature. Clin Nucl Med (2007) 1.44
18F-FDG PET-CT in the diagnosis of tumor thrombus: can it be differentiated from benign thrombus? Nucl Med Commun (2011) 1.44
Filamin A regulates focal adhesion disassembly and suppresses breast cancer cell migration and invasion. J Exp Med (2010) 1.43
MTA family of coregulators in nuclear receptor biology and pathology. Nucl Recept Signal (2007) 1.43
Heregulin and HER2 signaling selectively activates c-Src phosphorylation at tyrosine 215. FEBS Lett (2003) 1.43
Persistent renin-angiotensin system activation after anti-reflux surgery and its management. J Pediatr Urol (2011) 1.43
Radiation dose to family members of hyperthyroidism and thyroid cancer patients treated with 131I. Radiat Prot Dosimetry (2005) 1.43
Deregulation of estrogen receptor coactivator proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor in human endometrial tumors. J Clin Endocrinol Metab (2004) 1.41
Long term outcome of management of antenatally diagnosed pelvi-ureteric junction obstruction. Indian J Pediatr (2011) 1.41
Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase. J Med Chem (2008) 1.41
Functional implications of altered subcellular localization of PELP1 in breast cancer cells. Cancer Res (2005) 1.39
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother (2008) 1.39
Direct radionuclide cystography by supra-pubic puncture: comparison with conventional voiding cystourethrography. Nucl Med Commun (2004) 1.39
Role of travel as a risk factor for hepatitis E virus infection in a disease-endemic area. Indian J Gastroenterol (2002) 1.39
Repression of Six3 by a corepressor regulates rhodopsin expression. Proc Natl Acad Sci U S A (2007) 1.38
Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations. Clin Cancer Res (2006) 1.38
National leadership: driving forward the updated Global Strategy for Women's, Children's and Adolescents' Health. BMJ (2015) 1.38
Steering estrogen signals from the plasma membrane to the nucleus: two sides of the coin. J Cell Physiol (2006) 1.36
LIM kinase 1 increases tumor metastasis of human breast cancer cells via regulation of the urokinase-type plasminogen activator system. Int J Cancer (2006) 1.34
The molecular basis for ligand specificity in a mouse olfactory receptor: a network of functionally important residues. J Biol Chem (2006) 1.34
Nuclear localization and chromatin targets of p21-activated kinase 1. J Biol Chem (2005) 1.34
Par-4 transcriptionally regulates Bcl-2 through a WT1-binding site on the bcl-2 promoter. J Biol Chem (2003) 1.34
Insulin-like growth factor receptor as a therapeutic target in head and neck cancer. Clin Cancer Res (2007) 1.34
p41-Arc subunit of human Arp2/3 complex is a p21-activated kinase-1-interacting substrate. EMBO Rep (2004) 1.34
Insulin-like growth factor-1 regulates endogenous RUNX2 activity in endothelial cells through a phosphatidylinositol 3-kinase/ERK-dependent and Akt-independent signaling pathway. J Biol Chem (2004) 1.33
Identification of Pax5 as a target of MTA1 in B-cell lymphomas. Cancer Res (2007) 1.31
Cell cycle-dependent phosphorylation of the RUNX2 transcription factor by cdc2 regulates endothelial cell proliferation. J Biol Chem (2006) 1.31
Synthesis and in vitro anti-mycobacterial activity of 5-substituted pyrimidine nucleosides. Bioorg Med Chem (2005) 1.30
p21-activated kinase 1 interacts with and phosphorylates histone H3 in breast cancer cells. EMBO Rep (2002) 1.30